Tisagenlecleucel

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

Global Cell Counting Market to Hit $15.72 Billion by 2029, Fueled by Advancements in Cell Biology and Therapy - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Research, Technology, University, Genetics, Artificial Intelligence, Education, Science, Nanotechnology, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Automation, Quality control, Interdisciplinarity, Acute lymphoblastic leukemia, Growth, Prevalence, Application, Novartis, Patient, Conditional sentence, Cell biology, Lung, Concha bullosa, Hospital, Artificial intelligence, National Cancer Institute, AI, Regenerative medicine, Duchenne muscular dystrophy, Therapy, DEB, Miniaturization, Sarepta Therapeutics, CGT, FDA, DMD, Tisagenlecleucel, PDUFA, Pharmaceutical industry

The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.

Key Points: 
  • The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.
  • Advancements in cell biology, biotechnology, and medical research are driving demand for precise cell counting, especially with the rise of personalized medicine and regenerative therapies.
  • PDUFA dates for therapies could translate into an order book boost for the cell counting players in the market, resulting in market growth.
  • The global cell counting market is consolidated, with top five players holding approximately 70% share of the market.

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Health, Pharmaceutical, Research, Antibody, Immune system, Non-Hodgkin lymphoma, Therapy, Lymphoid leukemia, Loncastuximab tesirine, Scleroderma, CRS, JW, IND, Tafasitamab, Tisagenlecleucel, B-cell lymphoma, Patient, Systemic scleroderma, CD19, Blinatumomab, FDA, Lupus, Acute leukemia, SLE, Chronic lymphocytic leukemia, Novartis, Sjögren syndrome, Neurotoxicity, Quality of life, NHL, Fast Track, ALL, Cytokine release syndrome, CLL, Vaccine, Pharmaceutical industry, Amgen

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Response Rates - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Antibody, Tisagenlecleucel, IND, Acute leukemia, Fast Track, CD19, B-cell lymphoma, Hematological Cancer Research Investment and Education Act, Research, Neurotoxicity, Quality of life, Novartis, Indication, Immune system, Cytokine release syndrome, USD, NHL, CRS, Lymphoid leukemia, Therapy, Patient, Non-Hodgkin lymphoma, ALL, Monoclonal antibody, Vaccine, Pharmaceutical industry, Amgen

Market Opportunity: The global CD19 antibody market is projected to exceed USD 10 billion by 2028, showcasing its remarkable growth potential.

Key Points: 
  • Market Opportunity: The global CD19 antibody market is projected to exceed USD 10 billion by 2028, showcasing its remarkable growth potential.
  • Commercially Approved CD19 Antibodies: Currently, there are 10 approved CD19 antibodies available in the market, indicating a diverse range of treatment options for patients.
  • These therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell (CAR-T) therapies, have made a significant impact on cancer treatment.
  • To date, nine CD19-targeting therapies have received approval from regulatory bodies, including bispecific antibodies, monoclonal antibodies, antibody-drug conjugates, and CAR-T therapies.

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer 

Retrieved on: 
Monday, November 6, 2023
Graphics processing unit, University, TIL, ETH Zurich, Novartis, Change, Cancer, Therapy, Patient, SAN, Pharmaceutical industry, Vaccine, Tisagenlecleucel

SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.

Key Points: 
  • SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.
  • “We are excited to welcome Simone to T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • During her tenure, she built the company’s cell therapy production capabilities, hiring and training more than one hundred manufacturing associates.
  • She obtained her Ph.D. at ETH Zurich and completed her post doc work at the University of Alberta.

T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.

Retrieved on: 
Monday, November 6, 2023
Acute lymphoblastic leukemia, FDA, Research, CAR, Tisagenlecleucel, Bristol Myers Squibb, Gilead, Growth, Disease, Canadian Aviation Regulations, Infection, Cancer, Patient, B-cell lymphoma, Pharmaceutical industry, Vaccine, Biotechnology, Lisocabtagene maraleucel

WILMINGTON, DEL., Nov. 6, 2023 /PRNewswire/ --The global T cell therapy market was estimated to have acquired US$ 5.3 billion in 2022. It is anticipated to register a 27.9% CAGR from 2023 to 2033 and by 2033, the market is likely to gain US$ 76.6 billion.Expanding the infrastructure for T cell therapy administration, such as specialized treatment centers and healthcare provider training, can enhance patient access and outcomes.

Key Points: 
  • Research and clinical trials are exploring the use of T cell therapy in various disease indications beyond cancer, including autoimmune diseases, infectious diseases, and solid tumors.
  • Global Market for T Cell Therapy: Regional Outlook
    Various reasons are propelling the growth of the T cell therapy market in different regions.
  • The regions include,
    Biotech companies, academic institutions, and pharmaceutical firms in Europe have been investing in T cell therapy research and development.
  • Breyanzi is the second CAR T cell therapy to be approved by the FDA for the treatment of LBCL.

Global Rare Hemophilia Factors (I, II, VII) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Health, Genetics, FDA, Child, Plasma, Second Continental Congress, Orphan Drug Act of 1983, Health care, Haemophilia, ODA, Hand, Treatment, Congress, Prevalence, VII, Coagulation factor VII, Personal protective equipment, Coagulation, Infection, Quality of life, Growth, COVID-19, Factor VII deficiency, Patient, Diagnosis, Speciality chemicals, Pharmaceutical industry, Tisagenlecleucel, Safety, Cryoprecipitate

The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.
  • This intensified focus on patient safety measures is expected to have enduring benefits for rare hemophilia factor administration.

Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth

Retrieved on: 
Tuesday, October 3, 2023
Orphan Drug Act of 1983, Fresh frozen plasma, Infection, Hand, Prevalence, Personal protective equipment, Health care, COVID-19, Quality of life, Haemophilia, Coagulation, Second Continental Congress, Congress, Plasma, ODA, VII, Patient, Child, Coagulation factor VII, Factor VII deficiency, Growth, Diagnosis, FDA, Treatment, Speciality chemicals, Pharmaceutical industry, Safety, Tisagenlecleucel

The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.

Key Points: 
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • The surge in the market is primarily attributed to the increased availability of tailored factor concentrates securing regulatory approvals, notably from the U.S. FDA.
  • Additionally, the rising adoption of prophylaxis treatment among patients is expected to be a significant growth driver in the coming years.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.

ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development

Retrieved on: 
Tuesday, September 19, 2023
Process, Change, University, Therapy, Senior, CMC, Cancer, Immuno AG, MBA, Research, University residence hall network, Doctor of Philosophy, HSG, Molecular Partners, Novartis, Biology, FDA, Technical, Inflammation, Pharmaceutical industry, Vaccine, Tisagenlecleucel, MD

In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.

Key Points: 
  • In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.
  • We are excited to have her join the team and lead our CMC and technical development efforts to develop and manufacture novel protein- and antibody-based therapies," said Steve Coats, PhD, Chief Development Officer at ImmunOs.
  • Her breadth and depth of expertise in technical development, manufacturing and operations will be important for advancing our first-in-class pipeline of multi-functional immunotherapies to and through clinical development."
  • "I believe that ImmunOs´ expertise in pioneering HLA-based therapeutics focusing on both oncology and immunology, led by IOS-1002, ImmunOs´ lead clinical candidate in oncology, is at the forefront of current research," said Dr. Constanze Guenther, Senior Vice President, CMC and Technical Development at ImmunOs.

US Cell & Gene Therapy Market Report 2023-2028: Industry Expected to Grow at a CAGR of 41.25% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 23, 2023
Health, Pharmaceutical, Spark Therapeutics, Amgen, Gilead Sciences, PTC Therapeutics, BioMarin Pharmaceutical, Cancer, Organogenesis, Telephone numbers in South Africa, Bristol Myers Squibb, AAV, Stem cell, Food and Drug Administration Safety and Innovation Act, CAR, CDMO, Novartis, Blood, Cell, Conditional sentence, Growth, Rare, FDA, Therapy, Food, Vaccine, Pharmaceutical industry, Tisagenlecleucel

This report offers market size & forecast data for the cell & gene therapy market in the US.

Key Points: 
  • This report offers market size & forecast data for the cell & gene therapy market in the US.
  • The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.
  • This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023-2028 in the US.